We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
Small-Cap Growth ETF (PXSG) Hits New 52-Week High
For investors seeking momentum, Invesco Russell 2000 Pure Growth ETF is probably on the radar now. The fund just hit a 52-week high and is up nearly 38% from its 52-week low price of $28.57/share.
But are more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook on it to get a better idea on where it might be headed.
PXSG in Focus
The fund measures the performance of the U.S. small-cap growth companies. Health Insurance Innovations, Tandem Diabetes Care and Pacira Pharmaceuticals are the top three holdings of the fund. The product charges 39 bps in fees (see all small-cap ETFs here).
Why the Move?
Investors should note that the Fed is on track to raise rates faster as long as the U.S. economy continues to do well. Small-cap stocks are likely to do better in a rising rate environment since these are tied more to domestic activities and are thus not hurt in a rising dollar environment (which is a likely outcome). Also, with the GDP growth data coming in upbeat, investors have every reason to play this small-cap ETF.
More Gains Ahead?
The fund has a Zacks Rank #2 (Buy). Plus, it seems that the fund will perform decently in the near term given a positive weighted alpha of 37.90.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>